Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 2

Conditions

Melanoma 2

Interventions

Cyclophosphamide 909Carboplatin 786Paclitaxel 741pembrolizumab 741Bevacizumab 715Cisplatin 707Gemcitabine 621Docetaxel 583Rituximab 558Radiotherapy 546Dexamethasone 510Nivolumab 488Doxorubicin 445Fluorouracil 392Capecitabine 382Etoposide 357Pemetrexed 336Oxaliplatin 335Cytarabine 334Lenalidomide 327Prednisone 327Erlotinib Hydrochloride 323fludarabine phosphate 315Trastuzumab 305Leucovorin 299fludarabine 296Vincristine 288Bortezomib 284Filgrastim 284Cetuximab 275

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Adoptive Transfer × Clear all
NCT01005745 2025-12-19

Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase NA Completed
19 enrolled 7 charts
Dermatologic

Melanoma

NCT02354690 2020-03-23

Vemurafenib and TIL Therapy for Metastatic Melanoma

Herlev Hospital

Phase 1/2 Completed
13 enrolled 12 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡